Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.3680
-0.0250 (-6.36%)
At close: Jun 18, 2026, 4:00 PM EDT
0.3815
+0.0135 (3.67%)
After-hours: Jun 18, 2026, 7:16 PM EDT
Nexalin Technology Revenue
Nexalin Technology had revenue of $14.95K in the quarter ending March 31, 2026, a decrease of -63.55%. This brings the company's revenue in the last twelve months to $275.58K, up 110.26% year-over-year. In the year 2025, Nexalin Technology had annual revenue of $301.65K with 78.78% growth.
Revenue (ttm)
$275.58K
Revenue Growth
+110.26%
P/S Ratio
29.35
Revenue / Employee
$34,448
Employees
8
Market Cap
7.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 301.65K | 132.93K | 78.78% |
| Dec 31, 2024 | 168.72K | 57.97K | 52.35% |
| Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
| Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
| Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
| Dec 31, 2020 | 242.91K | 35.53K | 17.13% |
| Dec 31, 2019 | 207.38K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Trinity Biotech | 43.79M |
| Vivos Therapeutics | 19.57M |
| Tenon Medical | 4.60M |
| Biomerica | 4.33M |
| Intelligent Bio Solutions | 3.91M |
| VolitionRx | 2.47M |
| Sintx Technologies | 1.03M |
| Co-Diagnostics | 718.17K |
NXL News
- 2 days ago - Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life - GlobeNewsWire
- 8 days ago - Nexalin Technology completes neurostimulation protocol trial - TheFly
- 8 days ago - Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan. - GlobeNewsWire
- 10 days ago - Nexalin Technology Registration statement - Filings
- 10 days ago - Nexalin Technology Quarterly report - Filings
- 14 days ago - Nexalin Technology announces issuance of new U.S. patent - TheFly
- 14 days ago - Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia - GlobeNewsWire
- 4 weeks ago - Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury - GlobeNewsWire